Healthcare firms have done comparatively well in an otherwise subdued U.S. IPO market in 2024, which analysts touted as a comeback year for public offerings. The Richmond, California-based company ...

“These are scams,” said Kenny Biddle, the chief investigator for the Center of Inquiry, an organization devoted to defending ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

This summary of recent health news includes U.S. Senator Bernie Sanders advocating for cheaper Ozempic, new findings on ...

Two new papers by a team of researchers at Boston University, the Indiana University School of Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for ...

NanoVation Therapeutics partners with Novo Nordisk to develop genetic medicines for cardiometabolic and rare diseases, utilizing NanoVation's lipid nanoparticle technology. The deal includes research ...

Lawsuit is part of a nationwide strategy by Novo Nordisk to protect its trademark and profits from its blockbuster GLP-1 ...

Hennepin County Board approved a 5.5% increase to the 2025 property tax levy, which will raise more than $1 billion in ...

Ozempic is not approved for use in weight loss, however, many people have been taking the drug for this purpose. Semaglutide was approved for weight loss purposes under another name—Wegovy—which has a ...

Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...

The healthcare sector was also down, with a 0.7% drop, as Danish pharmaceutical firm Novo Nordisk saw its shares fall by 2.4% ...

Theratechnologies’ supply hiccup is the second caused by third-party manufacturing problems in less than a week. On Friday, ...